News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
82,011 Results
Type
Article (1126)
Company Profile (9)
Press Release (80876)
Multimedia
Podcasts (7)
Webinars (1)
Section
Business (29059)
Career Advice (130)
Deals (8377)
Drug Delivery (3)
Drug Development (6887)
Employer Resources (2)
FDA (1354)
Job Trends (1583)
News (38496)
Policy (2785)
Tag
2025 Best Places to Work (2)
2026 Best Places to Work (2)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Pharm Country Premier (1)
40 Under 40 (1)
Academia (96)
Accelerated approval (4)
ADA (2)
Allergies (4)
Alliances (5985)
ALS (13)
Alzheimer's disease (198)
Antibody-drug conjugate (ADC) (74)
Approvals (1457)
Artificial intelligence (45)
ASCO (29)
Autoimmune disease (37)
Automation (5)
Bankruptcy (87)
Best Places to Work (1411)
BIO (4)
Biologics (20)
BIOSECURE Act (1)
Biosimilars (42)
BioSpace Insights (1)
Biotechnology (5)
Bispecific (2)
Bladder cancer (11)
Brain cancer (15)
Breast cancer (89)
Cancer (763)
Cardiovascular disease (73)
Career advice (113)
Career pathing (1)
CAR-T (30)
CDC (2)
CDMO (7)
Celiac Disease (2)
Cell therapy (86)
Cervical cancer (8)
Clinical research (6578)
Collaboration (196)
Commercialization (6)
Compensation (128)
Complete response letters (10)
COVID-19 (120)
CRISPR (4)
C-suite (158)
Cystic fibrosis (11)
Data (1177)
Depression (15)
Dermatology (15)
Diabetes (50)
Diagnostics (800)
Digital health (13)
Diversity, equity & inclusion (1)
Drug discovery (29)
Drug pricing (11)
Duchenne muscular dystrophy (26)
Earnings (8389)
Editorial (2)
Employer branding (1)
Employer resources (2)
ESMO (49)
Events (11542)
Executive appointments (164)
FDA (1857)
Fibrodysplasia Ossificans Progressiva (2)
Fragile X (3)
Frontotemporal dementia (2)
Funding (243)
Gene editing (11)
Gene therapy (31)
GLP-1 (43)
Government (205)
Guidances (51)
Healthcare (2057)
Hematology (19)
HIV (4)
Huntington's disease (1)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (2)
Immunology and inflammation (21)
Immuno-oncology (14)
Indications (35)
Infectious disease (149)
Inflammatory bowel disease (44)
Influenza (16)
Intellectual property (76)
Interviews (23)
IPO (5013)
Job creations (211)
Job search strategy (94)
JPM (3)
Kidney disease (7)
Layoffs (12)
Leadership (2)
Legal (906)
Licensing (7)
Liver cancer (5)
Longevity (4)
Lung cancer (93)
Lymphoma (39)
Machine learning (3)
Manufacturing (105)
Marketing (7)
MASH (16)
Medical affairs (1)
Medical device (1934)
Medtech (1972)
Melanoma (3)
Mergers & acquisitions (4037)
Metabolic disorders (132)
mRNA (14)
Multiple sclerosis (15)
Multispecific (1)
NASH (1)
Netherlands (1)
Neurodegenerative disease (44)
Neuropsychiatric disorders (8)
Neuroscience (408)
Neurotech (1)
NextGen: Class of 2026 (907)
Non-profit (174)
Obesity (63)
Opinion (5)
Ovarian cancer (38)
Pain (42)
Pancreatic cancer (94)
Parkinson's disease (70)
Partnered (4)
Patents (139)
Patient advocacy (1)
Patient recruitment (74)
Patient selection (17)
Peanut (2)
People (7052)
Peptides (6)
Pharmacy benefit managers (7)
Phase 1 (2040)
Phase 2 (3072)
Phase 3 (2148)
Pipeline (1643)
Policy (9)
Postmarket research (147)
Preclinical (803)
Press Release (1)
Prostate cancer (25)
Psychedelics (4)
Radiopharmaceuticals (68)
Rare diseases (137)
Real estate (531)
Recruiting (1)
Regenerative medicine (5)
Regulatory (2403)
Reports (8)
Research institute (149)
Resumes & cover letters (15)
Rett syndrome (3)
RSV (9)
Schizophrenia (46)
Series A (39)
Series B (31)
Sickle cell disease (26)
Special edition (1)
Spinal muscular atrophy (8)
Startups (514)
State (1)
Stem cells (1)
Stomach cancer (1)
Substance use disorders (2)
Supply chain (15)
Switzerland (4)
Tariffs (1)
The Weekly (6)
Vaccines (62)
Weight loss (18)
Wet AMD (1)
Women's health (10)
Date
Today (3)
Last 7 days (76)
Last 30 days (396)
Last 365 days (3763)
2026 (3439)
2025 (3634)
2024 (4525)
2023 (5571)
2022 (6804)
2021 (7925)
2020 (7606)
2019 (5317)
2018 (4106)
2017 (3924)
2016 (3232)
2015 (4527)
2014 (3092)
2013 (2533)
2012 (2708)
2011 (2359)
2010 (2113)
Location
Africa (23)
Alabama (9)
Arizona (103)
Arkansas (1)
Asia (3886)
Australia (529)
California (2275)
Canada (325)
China (103)
Colorado (75)
Connecticut (126)
Delaware (48)
Europe (5890)
Florida (481)
Georgia (62)
Idaho (7)
Illinois (147)
India (7)
Indiana (131)
Japan (39)
Kansas (28)
Kentucky (12)
Louisiana (6)
Maine (57)
Maryland (253)
Massachusetts (1264)
Michigan (89)
Minnesota (132)
Mississippi (4)
Missouri (30)
Montana (3)
Nebraska (5)
Nevada (64)
New Hampshire (17)
New Jersey (616)
New Mexico (4)
New York (571)
North Carolina (409)
Northern California (1034)
Ohio (58)
Oklahoma (1)
Oregon (3)
Pennsylvania (512)
Puerto Rico (4)
Rhode Island (12)
South America (68)
South Carolina (23)
Southern California (1017)
Tennessee (73)
Texas (590)
United States (8268)
Utah (80)
Vermont (1)
Virginia (70)
Washington D.C. (2)
Washington State (134)
West Virginia (1)
Wisconsin (36)
Wyoming (3)
82,011 Results for "bridgebio llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight
If approved, BridgeBio Pharma’s BBP-418—which, according to one Jefferies analyst, boasts “pretty darn compelling” data—would be the first therapy for limb-girdle muscular dystrophy. The FDA has an action date of Nov. 27.
November 2, 2026
·
6 min read
·
Michael Gibney
Rare diseases
BioSpace
40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBio
BridgeBio has produced two young leaders on BioSpace’s 2026 40 Under 40 list. Morgan Paull and Christine Zhang attribute their early success to the company’s unique hub-and-spoke model and a drive to help patients with few treatment options. “It’s very personal,” Paull said.
November 16, 2026
·
4 min read
·
Heather McKenzie
Rare diseases
BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit
BridgeBio Pharma plans to file for approval in the third quarter. If granted, the oral drug could present a “highly differentiated” option over current achondroplasia therapies, according to Jefferies.
June 29, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
BridgeBio touts kidney benefits for Attruby, differentiating from amyloidosis competitors
BridgeBio’s Attruby preserves kidney function in patients with transthyretin amyloidosis cardiomyopathy, an effect that is “distinct” from other drugs in this space, according to Jefferies.
July 6, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug
The FDA’s priority review acceptance of BridgeBio’s BBP-418 is another step toward what William Blair previously dubbed a “diversified commercial portfolio.” It also adds to the rapidly building momentum in muscular dystrophy more broadly.
May 27, 2026
·
3 min read
·
Heather McKenzie
Earnings
BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
BridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra.
August 12, 2026
·
2 min read
·
Tristan Manalac
Press Releases
BridgeBio to Participate in November and December 2026 Investor Conferences
November 9, 2026
·
1 min read
Press Releases
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
October 30, 2026
·
35 min read
Cardiovascular disease
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival
Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.
May 12, 2026
·
2 min read
·
Tristan Manalac
Press Releases
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - November 6, 2026
November 8, 2026
·
1 min read
1 of 8,202
Next